Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.

Try Elite for Free

New feature: Introducing the Finviz Matrix

Prelude Therapeutics, Incorporated

Contributing Author

Recent Articles by Prelude Therapeutics, Incorporated

Sep-11	Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference PRLD GlobeNewswire
Sep-10	Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader PRLD -8.25% GlobeNewswire
Aug-11	Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update PRLD +10.14% GlobeNewswire
May-12	Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update PRLD GlobeNewswire
Apr-20	Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering PRLD GlobeNewswire
Apr-20	Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026 PRLD GlobeNewswire
Apr-15	Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer PRLD +25.45% GlobeNewswire
Mar-17	Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting PRLD PRLD -9.04% GlobeNewswire
Mar-10	Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026 PRLD +16.50% GlobeNewswire
Feb-03	Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor PRLD +12.81% GlobeNewswire
Dec-06	Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs PRLD GlobeNewswire
Nov-12	Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update PRLD +8.89% GlobeNewswire
Nov-04	Prelude Therapeutics Announces Strategic Business Update PRLD -55.78% GlobeNewswire
Nov-04	Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors PRLD -55.78% GlobeNewswire
Nov-03	Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting PRLD +150.31% GlobeNewswire
Oct-17	Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors PRLD -9.16% GlobeNewswire
Aug-14	Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update PRLD GlobeNewswire
Jun-02	Prelude Therapeutics to Participate in Upcoming Healthcare Conferences PRLD GlobeNewswire
May-06	Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update PRLD GlobeNewswire

Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)